-- Company Also Announces Participation in Upcoming Investor Conferences in October -- SAN DIEGO, Sept 29
SAN DIEGO, Sept 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc.
(Nasdaq: OREX), a biopharmaceutical company focused on the treatment of
obesity and other central nervous system-related disorders, today announced
its active calendar of events for October 2008, which includes six data
presentations and one sponsored symposium at The Obesity Society Annual
Scientific Meeting, as well as upcoming corporate presentations at noteworthy
investor conferences.
The Obesity Society Annual Scientific Meeting, Phoenix Convention Center
Saturday, October 4
Poster Presentation
Abstract: 317-P
Title: "The Naltrexone-Bupropion Combination Reduces the Prevalence of the
Metabolic Syndrome and Improves Cardiometabolic Markers in At-Risk
Subjects"
Time: 5:00-7:00 p.m. MT
Sunday, October 5
Symposium
Event Code: E1280
Title: "Reward and Obesity; Too Much of a Good Thing?"
Time: 6:15-7:45 a.m. MT
Location: Hyatt Regency Phoenix, Regency Ballroom A/B
Oral Presentation
Abstract: 61-OR
Presenter: Ronald Landbloom, M.D.
Title: "Long Term Weight Loss from a Dose Optimization Study with
Zonisamide SR and Bupropion SR"
Time: 11:00-11:15 a.m. MT
Poster Presentation
Abstract: 585-P
Title: "Relative Bioavailability of Sustained-release (SR) versus
Immediate-release (IR) Naltrexone (NAL) Formulations in Healthy Obese
Volunteers: Implications for Improved Tolerability?"
Time: 5:30-7:30 p.m. MT
Monday, October 6
Oral Presentation
Abstract: 104-OR
Presenter: Sonja K. Billes, Ph.D.
Title: "Leptin Regulates Food Intake Via Dopamine Receptor-Dependent
Mechanisms"
Time: 11:30-11:45 a.m. MT
Poster Presentation
Abstract: 847-P
Title: "Quality of Life Improvements from a Dose Optimization Study with
Zonisamide SR and Bupropion SR"
Time: 12:45-2:45 p.m. MT
Poster Presentation
Abstract: 848-P
Title: "Timing of Response from a Dose Optimization Study with Zonisamide
SR and Bupropion SR"
Time: 12:45-2:45 p.m. MT
Upcoming Corporate Presentations
JMP Securities Healthcare Sector Focus Conference
Le Parker Meridien, New York
October 6, 2008
10:00 a.m. ET
BIOCOM Investor Conference
Hyatt Regency La Jolla, San Diego
October 28, 2008
4:00 p.m. PT
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
development of pharmaceutical product candidates for the treatment of central
nervous system disorders, including obesity. The Company's lead combination
product candidates targeted for obesity are Contrave(R), which is in Phase 3
clinical trials, and Empatic(TM), which is in late-stage of Phase 2 clinical
development. Each product candidate is designed to act on a specific group of
neurons in the central nervous system with the goal of achieving appetite
suppression and sustained weight loss. Beyond obesity, Orexigen is developing
drug combinations for use in schizophrenia and obsessive-compulsive disorder.
Further information about the company can be found at http://www.Orexigen.com.
SOURCE Orexigen Therapeutics, Inc.
